Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANCEP-1
2023-506979-10-00Phase 2Authorised
- Sponsor
- Region Västra Götaland
- Start
- May 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of histamine dihydrochloride and aldesleukin in pancreatic cancer (PC), Periampullary Carcinoma, pancreatic adenocarcinoma (PDAC) and 2 more, sponsored by Region Västra Götaland. Primary endpoint: Safety and tolerability (adverse events). Planned start May 2024; status: authorised.
02
Drugs
histamine dihydrochloridealdesleukin
03
Conditions
pancreatic cancer (PC)Periampullary Carcinomapancreatic adenocarcinoma (PDAC)Ampullary cancer (AC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2023-506979-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506979-10-00.